Injured Myocardium‐Targeted Theranostic Nanoplatform for Multi‐Dimensional Immune‐Inflammation Regulation in Acute Myocardial Infarction
Advanced Science · 2025-03 · 12 (10)
DOI: 10.1002/advs.202414740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.01.2025. Verfasst von Tao Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing, 21000…. Hauptthemen laut MEDLINE: Myocardial Infarction, Theranostic Nanomedicine, Inflammation, Myocardium. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Innovation 2030-Major Projects, National Key Research and Development Program of China, State Key Laboratory of Analytical Chemistry for Life Science.
Abstract (Originalsprache)
Pyroptosis is a key mode of programmed cell death during the early stages following acute myocardial infarction (AMI), driving immune‐inflammatory responses. Cardiac resident macrophages (CRMs) are the primary mediators of cardiac immunity, and they serve a dual role through their shaping of both myocardial injury and post‐AMI myocardial repair. To appropriately regulate AMI‐associated inflammation, HM4oRL is herein designed, an innovative bifunctional therapeutic nanoplatform capable of inhibiting cardiomyocyte pyroptosis while reprogramming inflammatory signaling. This HM4oRL platform is composed of a core of 4‐Octyl itaconate (4‐OI)‐loaded liposomes, a middle layer consisting of a metal‐polyphenol network (MPN) film, and an optimized outer hybrid immune‐cell membrane layer. The unique properties of this hybrid membrane layer facilitated HM4oRL targeting to the injured myocardium during early‐stage AMI in mice, whereupon the release of 4‐Ol and modified MPN synergistically inhibited cardiomyocyte pyroptosis while suppressing inflammatory monocytes/macrophage responses at the infarcted site. Mechanistically, HM4oRL preserved cardiac metabolic homeostasis through AMPK signaling activation, establishing favorable microenvironmental conditions for the reprogramming of CRM‐mediated inflammation. Ultimately, HM4oRL treatment is able to resolve inflammation, enhance neovascularization, and suppress myocardial fibrosis, reducing the infarct size and enhancing post‐AMI cardiac repair such that it is an innovative approach to the targeted treatment of AMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing, 210002, China.
- Department of Radiology, Nanjing Jinling Hospital, Nanjing Medical University, 305 East Zhongshan Road, Nanjing, 210002, China.
- Department of Cardiology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing, 210002, China.
ORCID-Profile: Longjiang Zhang
Förderung
- Science and Technology Innovation 2030-Major Projects
- National Key Research and Development Program of China
- State Key Laboratory of Analytical Chemistry for Life Science
Zitieren
APA
Zheng, T., Sheng, J., Wang, Z., Wu, H., Zhang, L., Wang, S., Li, J., Zhang, Y., Lu, G., & Zhang, L. (2025). Injured Myocardium‐Targeted Theranostic Nanoplatform for Multi‐Dimensional Immune‐Inflammation Regulation in Acute Myocardial Infarction. Advanced Science, 12(10). https://doi.org/10.1002/advs.202414740
Vancouver
Zheng T, Sheng J, Wang Z, Wu H, Zhang L, Wang S, et al. Injured Myocardium‐Targeted Theranostic Nanoplatform for Multi‐Dimensional Immune‐Inflammation Regulation in Acute Myocardial Infarction. Advanced Science. 2025;12(10). doi:10.1002/advs.202414740
BibTeX
@article{Zheng2025,
author = {Zheng, Tao and Sheng, Jie and Wang, Zhiyue and Wu, Haoguang and Zhang, Linlin and Wang, Sheng and Li, Jianhua and Zhang, Yunming and Lu, Guangming and Zhang, Longjiang},
title = {Injured Myocardium‐Targeted Theranostic Nanoplatform for Multi‐Dimensional Immune‐Inflammation Regulation in Acute Myocardial Infarction},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {10},
doi = {10.1002/advs.202414740}
}
EUVIMED